Related Experiment Videos
Current issues in the management of hypertension
Insights
Major trials show mild hypertension benefits from treatment, but guidelines for initiating drug therapy remain unclear. Individualized assessment of risks and benefits is crucial for effective antihypertensive management.
Area of Science:
- Cardiology
- Pharmacology
- Public Health
Background:
- Major clinical trials evaluating antihypertensive therapy are reviewed.
- Current issues in managing mild and isolated systolic hypertension are discussed.
- Widespread use of antihypertensive agents follows trial data showing patient benefits.
Purpose of the Study:
- To review major trials on antihypertensive therapy.
- To discuss current issues in choosing therapy for mild and isolated systolic hypertension.
- To assess the benefits and risks of antihypertensive drug initiation.
Main Methods:
- Review of major clinical trials on antihypertensive therapy.
- Analysis of data from the Hypertension Detection and Follow-up Program.
- Evaluation of the Multiple Risk Factor Intervention Trial (MRFIT).
Main Results:
- Several trials indicate benefits of antihypertensive therapy for mild hypertension.
- The Hypertension Detection and Follow-up Program showed reduced coronary heart disease (CHD) deaths.
- The MRFIT trial did not find significant differences in CHD mortality between special and usual care groups.
- Concerns exist regarding diuretics' impact on outcomes, lipid alterations, and hypokalemia.
Conclusions:
- Clear guidelines for initiating antihypertensive drug therapy are lacking.
- Thiazide diuretics are recommended for mild to moderate hypertension.
- Individualized assessment of potential benefits versus short- and long-term risks is essential for antihypertensive treatment decisions.
Abstract:
Major trials evaluating antihypertensive therapy are reviewed, and the current issues surrounding the choice of therapy in mild and isolated systolic hypertension are discussed. Several major trials have shown that patients with mild hypertension benefit from therapy. These results have prompted widespread use of antihypertensive agents; however, there are still no clear guidelines on when drug therapy should be initiated. Only the Hypertension Detection and Follow-up Program has shown significant decreases in coronary heart disease (CHD) related deaths. Thiazide diuretics are recommended as agents of first choice in the stepped-care approach to the management of uncomplicated mild to moderate hypertension. The Multiple Risk Factor Intervention Trial evaluated the effects of modifying several cardiovascular risk factors in more than 12,000 high-risk men. It failed to document significant differences in CHD-related mortality in patients who received special care as compared with those who received usual care. Concerns have been raised about the contribution of antihypertensive therapy, particularly diuretics, to the lack of differences in therapeutic outcomes. There is renewed interest in lipid alterations secondary to antihypertensive agents and the effect of diuretic-induced hypokalemia. Antihypertensive therapy should be instituted with an individualized assessment of the potential benefits of therapy relative to the short- and long-term risks of treatment.